- Fordham University School of Law (J.D., cum laude)
- Harvard Business School (M.B.A. in Finance and Operations)
- Swarthmore College (B.A. in History)
- Court-Appointed Experts on Valuation Can Help Speed Up Complicated Cases
- Chapter 22s -- Why Do They Occur And Are They Necessarily a Bad Thing?
- Memo to CEO: How Can You Keep Turnaround Professionals Away From Your Door?
Anthony H.N. Schnelling
Founding Member
Anthony H.N. Schnelling is a Managing Director and a founding member of Bridge Associates LLC.
Currently, he is acting as the Examiner in the Dexter Distributing, Inc. case in Phoenix, AZ. Mr. Schnelling has been charged with investigating Dexter’s corporate governance and certain potential conflicts of interest in connection with events leading up to the filing of its Chapter 11 petition.
He also co-heads the Bridge team serving as financial advisor for the Chapter 7 Trustee for Refco, LLC, the largest Chapter 7 liquidation ever filed. Refco was a commodity futures broker which, along with its affiliates, experienced significant financial difficulties and filed Chapter 7 in November 2005 in the Southern District in New York.
He also heads the Bridge Wind Down Team completing the liquidation of the estate of Durango Georgia Paper, a $270 million pre-petition annual revenue company, on behalf of its unsecured creditors. In addition he serves as the Litigation/Liquidation Trustee for the post-confirmation estate of Impath, Inc. Impath was a provider of diagnostic services for oncological patients which filed for Chapter 11 protection in New York in September 2003 and is currently prosecuting a $27 million refund claim with the IRS and completing certain litigation against Impath’s accountants.
In addition, provides assistance and supervision to the Bridge team providing advisory services to Financial Guaranty Insurance Company in connection with that institution’s healthcare review process.
Co-heads the Bridge team serving as financial advisor to a monoline bond insurance company (secured party) in connection with their involvement with a $500 million Midwest-based health system.